01—Abstract
Summary
Summary of the 8-K filed November 18, 2025. Cited figures are marked; the original filing is the authoritative source.
On November 17–18, 2025, Bristol Myers Squibb (BMY) disclosed the results of its cash tender offers for its outstanding notes.
As of the November 17, 2025 Early Tender Deadline, holders tendered substantial principal across both pools. The company reduced the Pool 1 maximum from $4.0 billiona to about $3.99 billion, which was sufficient to accept all Pool 1 notes tendered early, and raised the Pool 2 maximum from $3.0 billion to about $3.51 billion. Under the amended terms, all tendered Pool 1 notes and all Pool 2 notes at acceptance priority levels 1 through 4 were accepted with no proration, while the 5.900% Notes due 2033 were accepted at a 50.84% proration factor, capped at $250 million.
Notes at priority levels 6 through 9 were not accepted. The tender offers are a liability-management action in which BMY retires higher-coupon and near-term debt using cash. Early settlement is scheduled for November 20, 2025, and the offers expire December 3, 2025, but the company expects no final settlement because the early tender caps were met.
The filing does not disclose the funding source for the purchases or the net effect on debt levels and interest expense. Those details would be in the Offer to Purchase or subsequent filings. For investors, the transaction is a debt management event rather than an operating or earnings event.
It shows strong bondholder participation at the offered pricing, which suggests the company could retire a meaningful amount of debt. Total consideration per $1,000b principal ranged from about $985.66 to $1,129.13, and the offer yields ranged from roughly 3.7% to 6.1%, reflecting the spread between older coupons and current market rates.
02—Key points
Key Highlights
- Pool 1 maximum reduced from $4.0B to ~$3.99B, sufficient to accept all validly tendered Pool 1 notes (~$5.0B tendered across six series at 100% proration)
- Pool 2 maximum increased from $3.0B to ~$3.51B, with all priority 1–4 notes accepted at 100% proration
- 5.900% Notes due 2033 accepted at ~50.84% proration, capped at $250M of $493.6M tendered
- Notes at Pool 2 priority levels 6–9 (5.750% 2031, 5.550% 2054, 5.200% 2034, 5.100% 2031) received no acceptance
- Early Settlement Date is November 20, 2025; offers expire December 3, 2025, but no final settlement is expected because the caps were met
- Total consideration per $1,000 principal ranged from about $985.66 (3.400% 2029) to $1,129.13 (6.400% 2063), including the early tender premium
- The filing does not disclose the funding source or the net impact on debt and interest expense; these details require the Offer to Purchase or later filings
03—Questions
Frequently Asked Questions
What did Bristol Myers Squibb announce in this 8-K?
BMY announced the early participation results, amendment, and early settlement of its cash tender offers for outstanding notes, along with the accepted amounts and pricing terms. The offers were governed by an Offer to Purchase dated November 3, 2025.
Why did BMY change the Pool 1 and Pool 2 maximum amounts?
BMY reduced the Pool 1 maximum slightly to about $3.99B, which matched the amount tendered early, so all Pool 1 notes were accepted. It raised the Pool 2 maximum to about $3.51B to accept all priority 1–4 notes tendered early plus up to $250M of the 2033 notes. The filing does not state the strategic reasoning behind these changes.
Will investors who tendered after the early deadline have their notes accepted?
No. The caps were met or exceeded by the early tenders, so BMY expects no final settlement and will not accept any tenders made after the November 17, 2025 Early Tender Deadline.
How much will BMY pay, and do holders receive accrued interest?
Accepted holders receive the total consideration per $1,000 principal, which includes the early tender premium. Accrued and unpaid interest up to the Early Settlement Date is paid separately, and the total consideration figures in the filing exclude it. Interest stops accruing on the Early Settlement Date.
What does this transaction mean for BMY's financial position?
The filing does not quantify the total cash outlay, the funding source, or the resulting change in debt or interest expense. Because the notes are cancelled and retired, the transaction reduces outstanding debt, but investors should check the Offer to Purchase or future 10-Q filings for the net effect on leverage and financing costs.
04—Continue